力諾特玻(301188.SZ):“輕量薄壁高檔藥用玻璃瓶項目”成功點火
格隆匯8月24日丨力諾特玻(301188.SZ)公佈,公司“輕量薄壁高檔藥用玻璃瓶項目”建設工作已經完成,2022年8月24日,用於中硼硅模製瓶生產的節能新型玻璃熔化全電熔窯爐成功點火。該項目主要用於中硼硅模製瓶生產,項目達產後,可年生產中硼硅藥用模製瓶約5080.87噸。
公司表示,該項目的成功點火,有利於填補公司在模製瓶領域的空白,完善公司產業佈局,提升公司在中硼硅藥用玻璃領域的市場競爭力,進一步提高公司的盈利水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.